Federal Supply Schedule 36F79723D017E
Award Date
1/15/23
Last Date to Order
7/14/23
Federal Agency
Veterans Integrated Service Network 12
Awardee
Provention Bio Inc.
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Pricing Type
Fixed Price with Economic Price Adjustment
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Multiple
Primary Consortia Member
Not listed
Similar IDVs
Provention Bio Inc. was awarded a 5-year, $5 million Federal Supply Schedule (FSS) contract under Schedule 65 I B for drugs, pharmaceuticals, and hematology-related products by the Department of Veterans Affairs (VA) VISN 12 in July 2023. This multiple-award IDIQ contract vehicle allows federal agencies to issue task orders for these products as needed. Additionally, the VA National Acquisition Center awarded two Blanket Purchase Agreements (BPAs) to Provention Bio against this FSS contract. The...
The National Acquisition Center, a civilian agency within the Department of Veterans Affairs, awarded a single-award Blanket Purchase Agreement (BPA) to Provention Bio Inc. to provide the pharmaceutical product TZIELD. The $5 million BPA has a period of performance through June 2024 and is one of two BPAs awarded against Provention Bio's existing $5 million Federal Supply Schedule 65 I B contract, which was initially awarded in July 2023 for a 5-year term. An additional $1.44 million BPA was...
This Blanket Purchase Agreement (BPA) was awarded by the Department of Veterans Affairs (VA) National Acquisition Center to Provention Bio Inc., a biopharmaceutical company, to provide the drug TZIELD. The single-award BPA has a ceiling value of $1,444,167.20 and a period of performance from January 2023 through July 2023. This BPA was issued against Provention Bio's 5-year, $5 million Federal Supply Schedule (FSS) contract under Schedule 65 I B for drugs, pharmaceuticals and...
The Department of Veterans Affairs (VA) awarded a Federal Supply Schedule (FSS) contract, valued at up to $3.5 million, to Calliditas Therapeutics US Inc., a foreign-owned, for-profit pharmaceutical company. The contract, under the Pharmaceuticals and Drugs (FSS-61-IB) schedule, facilitates the procurement of TARPEYO, an innovative treatment for uncontrolled protein in urine due to primary immunoglobulin A nephropathy, a serious renal condition impacting some veterans. In addition to the FSS...
The Federal Supply Schedule (FSS) contract and Blanket Purchase Agreement (BPA) awarded to Bluebird Bio, Inc. by the U.S. Department of Veterans Affairs (VA) demonstrate the agency's interest in leveraging the company's gene therapies and hematology products to address the medical needs of the veteran population. The first IDV is a multiple-award, Schedule 65 IB FSS contract with a potential value of $300,000, which allows the VA's Veterans Integrated Service Network 12 to procure drugs,...
The U.S. Department of Veterans Affairs (VA) has awarded a multiple award Federal Supply Schedule (FSS-61-IB) contract to Sobi, Inc., a foreign-owned, for-profit pharmaceutical company, with a ceiling value of $78 million through July 2025. This contract enables the VA to procure pharmaceuticals and drug products, such as TEGSEDI and ORFADIN, to support healthcare services for veterans. Additionally, the VA National Acquisition Center has awarded a single-award Blanket Purchase Agreement (BPA)...
The Department of Veterans Affairs awarded a multiple-award Federal Supply Schedule contract to Viela Bio, Inc. against the Pharmaceuticals and Drugs schedule for an estimated $12.98 million. This IDV establishes supply of pharmaceutical products to various VA medical centers nationwide through 2022. A single-award Blanket Purchase Agreement against the same FSS schedule was also awarded to Viela Bio for an estimated $4.35 million. This BPA facilitates streamlined delivery of the neuromyelitis...
The U.S. Department of Veterans Affairs (VA) has awarded a Federal Supply Schedule contract (FSS-61-IB) to UCB, Inc., a global biopharmaceutical company, for the procurement of pharmaceutical drugs and related products. The contract has a ceiling value of $625,636,910 and a period of performance through September 14, 2025. Under this contract, UCB, Inc. will supply a variety of pharmaceutical products to the VA, with a focus on drugs used to treat neurology and immunology disorders, such as...
The Federal Supply Schedule (FSS) contract, awarded by the Department of Veterans Affairs (VA) Veterans Integrated Service Network 12, allows the VA to procure drugs, pharmaceuticals, and hematology-related products from Bluebird Bio, Inc. through October 2028. The multiple-award, $300,000 contract under Schedule 65 IB enables the VA to acquire Bluebird Bio's gene therapies and hematology products to treat veterans with rare genetic disorders and blood diseases. Additionally, Bluebird Bio...
The U.S. Department of Veterans Affairs (VA) has awarded a multiple-award Federal Supply Schedule (FSS) contract, valued at $5.5 billion, to Gilead Sciences Inc. (Gilead) under GSA Schedule 61-IB for Pharmaceuticals and Drugs. This contract allows various federal agencies to procure a wide range of pharmaceutical products from Gilead, including antiviral medications, cancer immunotherapies, and treatments for pulmonary conditions. Additionally, the VA has awarded a single-award Blanket...
Name | Description | Awardee | Potential Value (Click to sort descending) | Award Date (Click to sort descending) | Last Date To Order (Click to sort descending) | Updated At (Click to sort descending) |
|---|---|---|---|---|---|---|
36F79723D017E-36E79723A0010 | Provention Bio Inc. | $1.4m | 1/20/23 | 7/14/23 | 7/13/23 |